

ECULIZUMAB

BRAND NAME	SOLIRIS
DRUG CLASS	Immunomodulator, monoclonal antibody
AVAILABILITY	Vial contains 300 mg/30 mL of eculizumab. Also contains monobasic sodium phosphate monohydrate, dibasic sodium phosphate heptahydrate, sodium chloride and polysorbate-80. Contains 5 mmol of sodium. ¹ The solution is clear and colourless. ¹
WARNING	<p>The occupational hazard of intermittent low dose exposure to eculizumab is not known. Wear a mask and gloves when preparing the infusion solution to minimise exposure.</p> <p>Meningococcal infection is the most serious adverse reaction. Vaccinate patients at least 2 weeks before starting therapy. Monitor for signs and symptoms of meningococcal infection.¹</p>
pH	7 ¹
PREPARATION	Dilute before use ¹
STABILITY	Vial: store at 2 to 8 °C. Protect from light. Do not freeze. Do not shake. ¹ Infusion solution: stable for 24 hours at 2 to 8 °C and at 18 to 25 °C. ¹
ADMINISTRATION	
IM injection	Not recommended
SUBCUT injection	Not recommended
IV injection	Contraindicated ¹
IV infusion	Dilute the dose with an equal volume of a compatible fluid to make a final concentration of 5 mg/mL. Gently invert the bag to mix. Do not shake. ¹ The final infusion volume is 60 mL (300 mg dose), 120 mL (600 mg dose) or 180 mL (900 mg dose). Infuse over 25 to 45 minutes. ¹ If an adverse reaction occurs, slow or stop the infusion; the total infusion time should not exceed 2 hours. ¹
IV use for infants and children	Dilute the dose with an equal volume of a compatible fluid to make a final concentration of 5 mg/mL. Infuse over 1 to 4 hours. ¹ If an adverse reaction occurs, slow or stop the infusion. The total infusion time should not exceed 4 hours. ¹
COMPATIBILITY	
Fluids	Glucose 5% ¹ , Ringer's ¹ , sodium chloride 0.45% ¹ , sodium chloride 0.9% ¹
Y-site	No information
INCOMPATIBILITY	
Fluids	No information
Drugs	No information
SPECIAL NOTES	Monitor the patient during and for at least 1 hour after the infusion. Infusion reactions are common and include chills, fever and flu-like symptoms. Stop or slow the infusion and treat accordingly. ¹ Anaphylactic reactions are rare but are a medical emergency. Stop the infusion and commence treatment immediately.

REFERENCES

1. Product information. Available from www.tga.gov.au. Accessed 22/07/2021.